TORONTO / Feb 29, 2024 / Business Wire / Biomind Labs Inc. (“ Biomind ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, today announced the successful conclusion of the Phase 2 clinical trial of its proprietary... Read More

TORONTO / Sep 27, 2023 / Business Wire / Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, provides a corporate update outlining its research and development, intellectual property and clinical trials... Read More

TORONTO / Sep 14, 2023 / Business Wire / Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine (“ 5-MeO-DMT ”)... Read More

TORONTO / Jun 30, 2023 / Business Wire / Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, today announced the results of matters voted on at its annual and special meeting of holders of common shares (“... Read More

TORONTO / Apr 25, 2023 / Business Wire / Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has commenced a Phase II clinical trial for its proprietary... Read More

TORONTO / Mar 31, 2023 / Business Wire / Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has successfully completed the optimization of a new extraction method to increase... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that it has successfully completed the development of a novel sublingual... Read More

Controlling shareholder provides loan facility Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that the U.S. Food and Drug... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce positive initial results from part I of its Phase II trial on its BMND01... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce a Pre-Investigational New Drug (“ Pre-IND ”) meeting granted by the U.S. Food... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the receipt of a Controlled Substances License and the commencement of an... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the completion of dose administration of 30 healthy subjects in the Company’s... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the addition of Dr. Thomas Laughren as Medical Advisor for Clinical Trials. As... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that a third Phase II clinical trial for its BMND08 candidate based on... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, announced today that it has commenced dose administration of the first subject in a Phase I/IIa... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that it will be participating in the “PSYCH Symposium: London 2022 – Unlocking the... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the commencement of a commercial clinical trial on its proprietary drug candidate BMND06,... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for mental health disorders and beyond, officially opens its new clinical psychedelic research facility in the University Hospital Onofre Lopes, taking a major step for the development of the next... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: CRSWF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for the treatment of mental health disorders and beyond, is pleased to announce that its second Phase II clinical trial on N, N-dimethyltryptamine (“ DMT ”) for treatment-resistant depression has been... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: CRSWF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for the treatment of mental health disorders and beyond, is pleased to announce positive results from in vivo studies. Biomind Labs’ BMND07 drug candidate, a novel DMT combination drug, proved to be... Read More